Grace Therapeutics Inc. (GRCE)
NASDAQ: GRCE
· Real-Time Price · USD
3.23
0.15 (4.87%)
At close: Aug 15, 2025, 3:01 PM
Grace Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
April - March.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
Net Income | -3.36M | 636K | -4.16M | -3.43M | -2.62M | -3.17M | -2.39M | -3.27M | -4.02M | -29.09M | -3.89M | -4.93M | -4.52M | -3.9M | -3.78M | 981K | -3.12M |
Depreciation & Amortization | 2K | 2K | 2K | 2K | 1K | 1K | 1K | 2K | 7K | 8K | 10K | -61K | 167K | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 302K | 130K | 160K | 202K | 238K | 229K | 326K | 280K | 78K | 322K | 443K | 582K | 464K | 616K | 454K | 114K | 153K |
Other Working Capital | n/a | -241K | -809K | 222K | 574K | 467K | 628K | -464K | -1.99M | 387K | -126K | 1.06M | -837K | 1.34M | -1.26M | -2.22M | -626K |
Other Non-Cash Items | 1.26M | -2.64M | 1.18M | -362K | -1.39M | 1.03M | -126K | 1.79M | 13K | 33.95M | 23K | -10K | -20K | -889K | -577K | -4.6M | 97K |
Deferred Income Tax | n/a | -1.02M | -605K | -852K | -724K | -889K | -208K | -446K | -289K | -8.87M | -274K | -155K | -242K | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | -66K | -695K | 203K | 900K | 704K | 506K | -464K | -2.03M | 353K | -35K | 1.13M | -1.27M | 1.03M | -683K | -2.6M | -533K |
Operating Cash Flow | -1.8M | -2.95M | -4.12M | -4.24M | -3.6M | -2.09M | -1.89M | -2.11M | -6.24M | -3.33M | -3.72M | -3.44M | -5.43M | -3.15M | -4.58M | -6.1M | -3.4M |
Capital Expenditures | n/a | n/a | -4.84 | 3.70 | n/a | -22K | n/a | n/a | n/a | -8K | n/a | -2K | -7K | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | 1.91K | n/a | 110.07K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | -23.44 | -15K | n/a | -6.55M | n/a | n/a | n/a | -5M | 2K | -16K | -77K | -13.32M | -13.23M | -8.3M |
Sales Maturities Of Investments | n/a | 15K | 15K | n/a | n/a | 6.57M | n/a | n/a | n/a | 5M | n/a | -96K | 13.28M | 88K | 13.88M | 16.06M | 1.37M |
Other Investing Acitivies | n/a | -15K | n/a | n/a | n/a | -912 | n/a | -73 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | 15K | -23.44 | -15K | 6.55M | -6.55M | 110K | n/a | 4.99M | -5M | -96K | 13.26M | 11K | 557K | 2.84M | -6.93M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -327K | -967K | n/a | n/a | n/a | n/a | n/a | 21K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Financial Cash Flow | -327K | 14.03M | n/a | n/a | n/a | 61.03K | -65.33K | 7.36M | n/a | n/a | n/a | 109K | 195K | n/a | n/a | n/a | n/a |
Net Cash Flow | -2.13M | 11.08M | -4.1M | -4.24M | -3.61M | 4.46M | -8.45M | 5.36M | -6.24M | 1.63M | -8.69M | -3.45M | 8.04M | -2.67M | -3.92M | -4.05M | -9.97M |
Free Cash Flow | -1.8M | -2.95M | -4.12M | -4.24M | -3.6M | -2.11M | -1.89M | -2.11M | -6.24M | -3.33M | -3.72M | -3.44M | -5.43M | -3.15M | -4.58M | -6.1M | -3.4M |